GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc filed a Form 6-K reporting two insider share sales on the London Stock Exchange. David Redfern, President of Corporate Development, sold 100,000 ordinary shares at £21.09 per share on 2026-02-05.
On the same date, Neil Falkingham, a person closely associated with Lynn Baxter (President, Europe), sold 2,000 ordinary shares at £20.87 per share. Both transactions involved GSK ordinary shares of 31¼ pence each and were executed on XLON.
GSK reports solid 2025 results with growth led by Specialty Medicines and confirms its medium-term outlook. Turnover reached £32.7 billion, up 7% at constant exchange rates, while Core operating profit rose 11% and Core EPS increased 12% to 172.0p.
Specialty Medicines sales grew 17% at constant exchange rates to £13.5 billion, driven by double‑digit gains in HIV, Respiratory, Immunology & Inflammation, and Oncology, where sales rose 43%. Vaccines delivered 2% growth, with strong ex‑US demand for Shingrix, meningitis vaccines and Arexvy offsetting weaker US shingles and RSV trends.
Free cash flow climbed to £4.0 billion, supporting dividends of 66p per share for 2025, a Q4 dividend of 18p, and a planned 70p dividend for 2026, alongside a £2 billion share buyback of which £1.4 billion is executed. For 2026, GSK guides to turnover growth of 3–5% and Core EPS growth of 7–9% at constant exchange rates and reiterates a 2031 sales outlook of more than £40 billion.
GSK plc reports its share capital and voting rights position as of 31 January 2026. The company had 4,316,103,805 ordinary shares of 31¼ pence each in issue, with 240,019,489 shares held in treasury. This leaves 4,076,084,316 voting rights currently available to shareholders.
Shareholders can use this voting rights figure as the denominator when calculating whether they must notify new or changed holdings under UK disclosure rules.
GSK plc reports that its RSV vaccine Arexvy has been approved by the European Commission for expanded use in adults aged 18 years and older. The vaccine was previously authorised in the European Economic Area for preventing lower respiratory tract disease caused by RSV in adults 60 and over and in adults 50 to 59 at increased risk.
This broader indication means European countries can now make Arexvy available to all adults 18+, potentially addressing a substantial disease burden. In the European Union, an average of 158,000 adults aged 18 and over are hospitalised each year with RSV-related illness. GSK notes that RSV can worsen chronic conditions such as COPD, asthma and chronic heart failure and can lead to pneumonia, hospitalisation and death.
The company highlights that Arexvy combines a recombinant RSV glycoprotein F antigen with GSK’s AS01E adjuvant, and that its use should follow official recommendations since not all vaccinees may develop protective immunity. GSK is also seeking expanded indications for this RSV vaccine in other geographies, including the US and Japan.
GSK plc has entered a definitive agreement to acquire RAPT Therapeutics for $58.00 per share in cash, valuing RAPT at an estimated aggregate equity value of $2.2 billion and implying an upfront investment of $1.9 billion net of cash acquired. The deal gives GSK global rights to ozureprubart, a long-acting anti-IgE monoclonal antibody in phase IIb development for prophylactic protection against food allergens, excluding mainland China, Macau, Taiwan and Hong Kong.
Ozureprubart is designed to be dosed every 12 weeks versus the current anti-IgE standard requiring injections every 2 to 4 weeks, and targets a large unmet need in food allergies, which affect over 17 million people in the US. GSK will launch a tender offer for all outstanding RAPT shares and then complete a second-step merger, with the transaction subject to customary conditions, including a majority tender and US antitrust clearance, and expected to close in the first quarter of 2026.
GSK has agreed with Pfizer and Shionogi to reshape their stakes in HIV specialist ViiV Healthcare. Pfizer’s 11.7% economic interest will be replaced by new ViiV shares issued to Shionogi for $2.125 bn. After the deal, GSK will retain a 78.3% majority economic interest in ViiV Healthcare and Shionogi’s economic interest will increase to 21.7%.
As part of the consideration, Pfizer will receive $1.875 bn in cash and GSK will receive a special dividend of $0.250 bn, payable in GBP. Completion is subject to regulatory clearances in relevant markets and is expected in the first quarter of 2026. On completion, GSK plans to extinguish the Pfizer put option liability through retained earnings, with any final fair value adjustment recorded as an adjusting item in other operating income.
GSK plc reported several small share acquisitions by senior leaders through its dividend reinvestment arrangements. The transactions involved American Depositary Shares (ADSs) listed on the New York Stock Exchange.
Non-Executive Director Dr Hal Barron acquired 2,832.219 ADSs at $50.2949 per ADS on 14 January 2026, following the reinvestment of dividends paid on 8 January 2026. James Ford, SVP and Group General Counsel, acquired 285.772 ADSs at the same price and date.
Maria Martinez-Davis, President, US, acquired 44.836 ADSs at $50.2949 on 14 January 2026 and additional amounts of 91.071 and 155.817 ADSs at $50.2200 on 9 January 2026. Shobie Ramakrishnan, Chief Digital and Technology Officer, acquired 344.244 ADSs at $50.2949 on 14 January 2026. All transactions were executed on the NYSE.
GSK plc reported small insider share acquisitions by two senior executives through a dividend reinvestment arrangement. David Redfern, President Corporate Development, acquired 17 ordinary shares at £18.845 each following the reinvestment of dividends paid on 8 January on shares held within an ISA, with the transaction dated 9 January 2026 on the London Stock Exchange.
Victoria Whyte, SVP & Company Secretary, similarly acquired 15 ordinary shares at £18.845 each via dividend reinvestment on 9 January 2026, also relating to dividends paid on 8 January 2026 on ISA-held shares. These are routine, small-volume personal transactions in GSK ordinary shares.
GSK plc reports multiple routine share transactions by senior leaders and board members. Executives and persons closely associated with them acquired small numbers of GSK ordinary shares of 31¼ pence each and American Depositary Shares through dividend reinvestment and the company’s Share Reward Plan.
Dividend-related acquisitions on 8 January 2026 were priced around £18.9433 and £18.9464 per ordinary share and about $50.2200–$50.4345 per ADS, with some awards recorded as increases in notional interests in the Deferred Annual Bonus Plan. Additional ordinary shares were acquired on 12 January 2026 under the Share Reward Plan at £18.9321, including both partnership and matching shares.
GSK plc reports that the European Commission has approved a new prefilled syringe presentation of Shingrix, its Recombinant Zoster Vaccine for shingles. The current version requires healthcare professionals to reconstitute a lyophilised antigen with a liquid adjuvant from two separate vials. The new format comes as a prefilled syringe, removing the reconstitution step and making administration simpler and more convenient in clinical settings.
The approval is based on data showing technical comparability between the prefilled syringe and the existing presentation, with no changes to the vaccine’s indication or dosing. Shingrix continues to be authorised in the European Union to prevent herpes zoster and post‑herpetic neuralgia in adults from age 50, and from age 18 for those at increased risk. GSK plans to begin rolling out the prefilled syringe across EU countries in 2026, aiming to support broader and easier protection against shingles, which affects around 1.7 million people in Europe each year.